## Abstract Intravenous administration of human mesenchymal stem cells (hMSCs) prepared from adult bone marrow has been reported to ameliorate functional deficits after cerebral artery occlusion in rats. Several hypotheses to account for these therapeutic effects have been suggested, and current th
Generation of insulin-producing cells from PDX-1 gene-modified human mesenchymal stem cells
✍ Scribed by Yanhua Li; Rui Zhang; Haifa Qiao; Heping Zhang; Yunfang Wang; Hongfeng Yuan; Qinbin Liu; Daqing Liu; Lin Chen; Xuetao Pei
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 382 KB
- Volume
- 211
- Category
- Article
- ISSN
- 0021-9541
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Islet cell replacement is considered as the optimal treatment for type I diabetes. However, the availability of human pancreatic islets for transplantation is limited. Here, we show that human bone marrow‐derived mesenchymal stem cells (hMSCs) could be induced to differentiate into functional insulin‐producing cells by introduction of the pancreatic duodenal homeobox‐1 (PDX‐1). Recombinant adenoviral vector was used to deliver PDX‐1 gene into hMSCs. After being infected with Ad‐PDX‐1, hMSCs were successfully induced to differentiate into insulin‐secreting cells. The differentiated PDX‐1^+^ hMSCs expressed multiple islet‐cell genes including neurogenin3 (Ngn3), insulin, GK, Glut2, and glucagon, produced and released insulin/C‐peptide in a weak glucose‐regulated manner. After the differentiated PDX‐1^+^ hMSCs were transplanted into STZ‐induced diabetic mice, euglycemia can be obtained within 2 weeks and maintained for at least 42 days. These findings validate the hMSCs model system as a potential basis for enrichment of human beta cells or their precursors, and a possible source for cell replacement therapy in diabetes. J. Cell. Physiol. 211: 36–44, 2007. © 2007 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract Aggregate culture is a useful method for inducing chondrogenic differentiation of human mesenchymal stem cells (hMSC) in a three‐dimensional __in vitro__ culture environment. Conventional aggregate culture, however, typically requires repeated growth factor supplementation during media
## Abstract Recent evidence indicates that a major drawback of current cartilage‐ and intervertebral disc (IVD) tissue engineering is that human mesenchymal stem cells (MSCs) from patients with osteoarthritis rapidly express type X collagen (COL10A1), a marker of late stage chondrocyte hypertrophy